Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Fluorodeoxyglucose F18 3Doxorubicin 3Cyclophosphamide 3surufatinib 2fludarabine 2entrectinib 2Radiotherapy 2Nivolumab 2Ifosfamide 2Filgrastim 2Drug Therapy 2Cisplatin 2tivozanib 1tislelizumab 1tipifarnib 1selpercatinib 1romidepsin 1repotrectinib 1regorafenib 1pembrolizumab 1milademetan 1ganitumab 1fludarabine phosphate 1entinostat 1dostarlimab 1conatumumab 1cixutumumab 1cabozantinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × LY2940680 × Endocrine × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡